可编程的分层水凝敷料用于连续释放生长因子和DNase,以加速糖尿病伤口愈合
Ying Zhang1, Shiqi Lin1, Xiao Xu1
1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
概括
这项研究开发了一种新的水凝来治疗糖尿病足 (DFU). 水凝提供了血小板衍生生长因子 (PDGF) 和脱氧核糖酶I (DNase I),以加速伤口愈合和预防皮肤损伤.
科学领域:
- 生物材料科学 生物材料科学
- 伤口治愈研究研究 伤口治愈研究
- 再生医学是一种再生医学.
背景情况:
- 糖尿病足 (DFU) 由于生长因子失调而表现出受损的愈合.
- 血小板衍生生长因子 (PDGF) 凝有助于DFU的愈合,但高血糖引起的中性粒细胞过活化和NET会导致进一步的损伤.
- 现有的治疗方法难以平衡中性粒细胞的招募和过度的NET形成.
研究的目的:
- 设计一个分层组装的水凝,用于局部,受控的PDGF-BB和脱氧核糖酶 (DNase) I. I. 的联合递送.
- 通过管理中性粒细胞外细胞陷 (NETs) 和促进组织修复,研究水凝在增强DFU愈合方面的有效性.
- 开发一种治疗策略,以加快糖尿病患者的伤口关闭.
主要方法:
- 通过无铜点击反应制造水凝,交叉连接四分化奇托和纳米凝.
- 将PDGF-BB装入水凝矩阵,并将DNase I装入纳米凝,以获得不同的释放动力学.
- 在糖尿病小鼠伤口模型中评估水凝的性能,评估中性粒细胞的招募,内皮细胞迁移,NET降解和伤口关闭.
主要成果:
- 工程水凝证明了PDGF-BB和DNase I在响应伤口微环境时的可编程释放.
- 同时提供PDGF-BB和DNase I促进了中性粒细胞的招募和内皮细胞迁移.
- 在糖尿病小鼠中,水凝有效降解了多余的NETs,防止了伤口感染,并显著加快了伤口关闭.
结论:
- 层次组装的水凝为DFU治疗中的组合治疗提供了一个有希望的平台.
- 同时输送PDGF-BB和DNase I解决了DFU的关键病理方面,包括受损的愈合和NET诱导的损伤.
- 这种方法有可能改善糖尿病足患者的临床结果.
更多相关视频
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172


